DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study
- PMID: 19243478
- DOI: 10.1111/j.1610-0387.2009.07034.x
DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study
Abstract
Background: Keloids and hypertrophic scars (HTS) can cause functional impairment and psychosocial burdens, both of which affects quality of life (QoL). Our aim was to compare Dermatology Life Quality Index (DLQI) scores in patients with keloids and HTS to those of psoriasis patients and normal controls.
Patients and methods: Forty-eight consecutive patients with keloids and HTS and 48 with psoriasis vulgaris attending our dermatology outpatient clinic, as well as 48 sex- and age-matched healthy controls completed the DLQI.
Results: Total DLQI scores of patients with keloids and HTS (7.79 +/- 5.10) and psoriasis (8.73 +/- 5.63) were comparable and significantly higher than that of healthy controls (0.58 +/- 0.77). No significant difference were found between patients with psoriasis and patients with keloids and HTS in terms of the total DLQI scores and the subscale scores (p > 0.05) except "treatment" (p < 0.05) sub-scale scores which were higher in psoriasis.
Conclusions: The QoL of patients with keloids and HTS is impaired as much as that of those with psoriasis. The DLQI questionnaire is a reliable and valid instrument for assessing the QoL in patients with keloids and HTS.
Similar articles
-
The dermatology life quality index as a means to assess life quality in patients with different scar types.J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2112-9. doi: 10.1111/jdv.13135. Epub 2015 Apr 10. J Eur Acad Dermatol Venereol. 2015. PMID: 25866177
-
Psoriasis affects patient's quality of life more seriously in female than in male in Japan.Tokai J Exp Clin Med. 2012 Sep 20;37(3):84-8. Tokai J Exp Clin Med. 2012. PMID: 23032250
-
Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.J Eur Acad Dermatol Venereol. 2013 Jan;27(1):109-15. doi: 10.1111/j.1468-3083.2011.04371.x. Epub 2011 Dec 7. J Eur Acad Dermatol Venereol. 2013. PMID: 22145712
-
Treatment of hypertrophic scars and keloids.Duodecim. 2016;132(16):1439-47. Duodecim. 2016. PMID: 29188931 Review.
-
Standard guidelines of care: Keloids and hypertrophic scars.Indian J Dermatol Venereol Leprol. 2011 Jan-Feb;77(1):94-100. doi: 10.4103/0378-6323.74968. Indian J Dermatol Venereol Leprol. 2011. PMID: 21220896 Review.
Cited by
-
Animal Models for Studies of Keloid Scarring.Adv Wound Care (New Rochelle). 2019 Feb 1;8(2):77-89. doi: 10.1089/wound.2018.0828. Epub 2019 Feb 13. Adv Wound Care (New Rochelle). 2019. PMID: 31832272 Free PMC article. Review.
-
Keloid treatments: an evidence-based systematic review of recent advances.Syst Rev. 2023 Mar 14;12(1):42. doi: 10.1186/s13643-023-02192-7. Syst Rev. 2023. PMID: 36918908 Free PMC article.
-
Use of Adipose Stem Cells Against Hypertrophic Scarring or Keloid.Front Cell Dev Biol. 2022 Jan 6;9:823694. doi: 10.3389/fcell.2021.823694. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35071247 Free PMC article. Review.
-
The transcriptional profile of keloidal Schwann cells.Exp Mol Med. 2022 Nov;54(11):1886-1900. doi: 10.1038/s12276-022-00874-1. Epub 2022 Nov 4. Exp Mol Med. 2022. PMID: 36333467 Free PMC article.
-
The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models.Front Cell Dev Biol. 2020 May 26;8:360. doi: 10.3389/fcell.2020.00360. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32528951 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical